| Dr Samara Spring Churgin, MD | |
|
400 W Main St, Suite 120, Babylon, NY 11702-3012 | |
| (631) 661-0202 | |
| (631) 661-0559 |
| Full Name | Dr Samara Spring Churgin |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 23 Years |
| Location | 400 W Main St, Babylon, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356518286 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 240889 (New York) | Primary |
| Entity Name | Samara Spring Churgin Medical Doctor Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063712834 PECOS PAC ID: 7618161738 Enrollment ID: O20101103000276 |
News Archive
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Physicians at the Hypertension and Vascular Disease Center at Wake Forest University Baptist Medical Center have proven that a new medical device improves blood pressure management in patients with the most common form of uncontrolled hypertension.
› Verified 1 days ago
| Entity Name | Schweiger Dermatology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831438662 PECOS PAC ID: 5991947160 Enrollment ID: O20130819000251 |
News Archive
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Physicians at the Hypertension and Vascular Disease Center at Wake Forest University Baptist Medical Center have proven that a new medical device improves blood pressure management in patients with the most common form of uncontrolled hypertension.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samara Spring Churgin, MD 400 W Main St, Suite 120, Babylon, NY 11702-3012 Ph: (631) 661-0202 | Dr Samara Spring Churgin, MD 400 W Main St, Suite 120, Babylon, NY 11702-3012 Ph: (631) 661-0202 |
News Archive
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Physicians at the Hypertension and Vascular Disease Center at Wake Forest University Baptist Medical Center have proven that a new medical device improves blood pressure management in patients with the most common form of uncontrolled hypertension.
› Verified 1 days ago